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Abstract Clinical and radiological features that help predict
the growth potential of meningioma would be beneficial.
The purpose of this study is to clarify the characteristics
related to proliferating potential using the MIB-1 staining
index. We analyzed the relationship of MIB-1 staining
indices to characteristics of 342 consecutive patients with
meningioma surgically removed between 1995 and 2004 by
logistic regression analysis. One hundred and forty-nine of
the patients with meningioma were ≥60 in age; 89 male; 48
recurrent; 203 symptomatic; 157 at the skull base; 124 over
20 cm
3; 24 multiple; 136 with edema; 117 with calcifica-
tion. The MIB-1 staining index in 56 of 296 grade I
meningiomas in WHO classification was ≥ 3.0; in 27 of 28
grade II; and in 17 of 18 grade III, respectively. Logistic
regression analysis demonstrated that male (odds ratio
[OR], 2.374, p=0.003), recurrence (OR, 7.574, p=0.0001),
skull base (OR, 0.540, p=0.035), calcification (OR, 0.498,
p=0.019) were independent risk factors for a high MIB-1
staining index (≥3.0); age, symptomatic, volume, multiple,
edema were not. Male, recurrence, non-skull base, absence
of calcification are independent risk factors for a high
proliferative potential. These should be taken into consid-
eration when managing meningiomas.
Keywords Growth.Meningioma.MIB-1
Introduction
An estimated 2–3% of the population has an incidental
asymptomatic meningioma in autopsy studies [14, 20].
With the wider use of CT and MRI, many meningiomas are
discovered as incidental findings during investigation for
unrelated symptoms [9, 13, 16, 17, 20, 21]. The growth
potential of meningiomas varies. Some meningiomas
remain unchanged in size for a long period, whereas others
grow rapidly [15]. Sex, age, initial tumor size, and
calcification were reported to be related to the tumor
growth judging from follow-up scans [9, 13, 16, 17, 21].
The nuclear antigen Ki-67 expressed by proliferating
cells has become available for routinely processed paraffin
section. The MIB-1 antibody detects an epitope on the Ki-
67 antigen, a nuclear protein present only during active
phase of the cell cycle (G1, S, G2, and M) [2]. Several
studies investigated how Ki-67 labelling indices could help
to predict recurrence [1, 3, 4, 6–8, 11, 12, 18, 19]. An
increased MIB-1 staining index was highly correlated with
a shorter tumor volume doubling time [12]. In the cases that
showed an MIB-1 of ≥ 3%, the tumor volume doubling
time was <2 years. Nakaguchi et al. [12] found the formula
which can calculate tumor doubling time (Td) from the
MIB-1 staining index at surgery: log Td=31.4–0.14×MIB-1
SI (R
2=0.556). The time interval to the next recurrence for
recurrent meningiomas is associated with the MIB-1
staining index. Meningiomas with MIB-1 staining index
of 3% or higher had a significantly higher tendency of
recurrence [11]. Although these cell kinetics methods are
valuable for growth potential, they can be applied only after
the verification of pathology [15].
The purpose of this study was to clarify the clinical and
radiological features related to meningioma proliferation
using the MIB-1 staining index. Sex, age, calcification,
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reported to be related to the tumor growth and MIB-1
staining index [1, 3, 4–8, 11–13, 16–19, 21]. The results,
however, were inconsistent because of a lack of sufficient
case number and inadequate statistical analysis. Indepen-
dent risk factors for high growth rate should be determined.
We analyzed the relationship of MIB-1 staining indices to
the characteristics of 342 consecutive patients with menin-
gioma surgically removed between 1995 and 2004 by
logistic regression analysis.
Materials and methods
Three hundred and forty-two patients with meningiomas
were surgically treated in our department of neurosurgery
between 1995 and 2004. Radiological features were
analyzed by CT scans and/or MRI. Location of the tumor
was classified as follows: convexity, falx, parasagittal,
sylvian fissure, tentorial, ventricular, foramen magnum,
olfactory groove, petroclival, petrous, sphenoid ridge, and
tuberculum sellae. The latter six locations were considered
as skull base. The tumor volume was calculated using the
formula: length × depth × width × 0.5 [9]. When patients
had multiple meningiomas, only the largest tumor was
included. On the basis of conventional CT and bone
window CT, patients were divided into two groups
according to the low density area around the tumor and
calcification in the tumor. A low density area due to
surgical scar was not included in edema in patients with
recurrent meningioma.
The tumors were histologically classified according to
the World Health Organization classification of tumors
[10]. An avidin-biotin immunoperoxidase or simple stain
MAX-peroxidase (Nichirei, Tokyo) technique was used to
perform MIB-1 monoclonal antibody (DAKO, Denmark)
assay in selected sections of each case. All tissue sections
were examined at high-power magnification (×400). The
number of cells stained positively with MIB-1 and the total
number of tumor cells were counted in several representa-
tive fields containing more than 1,000 cells. Their ratio was
indicated as the MIB-1 staining index (%).
Statistical analysis
All data were stored on a personal computer and analyzed
using commercially available statistical software (SPSS
version 12.0, SPSS Inc.). Chi-squired analysis was used to
compare the MIB-1 staining index to characteristics of
patients with meningioma. All variables were included in a
logistic regression model to determine which variables were
independently associated with a high MIB-1 staining index
(≥3.0). Significance was judged at a value of p<0.05 for all
analyses.
Results
Table 1 shows the characteristics and MIB-1 staining
index of the 342 patients. One hundred and forty-nine of
patients with meningioma were ≥60 in age; 89 male; 48
recurrent; 203 symptomatic; 157 at the skull base;
124≥20 cm
3 in volume; 24 multiple; 136 with edema;
117 with calcification. We compare these characteristics to
the MIB-1 staining index. We divided them into two
groups: <3.0 and ≥3.0 [11]. The MIB-1 staining index in
100 of 342 meningiomas was > 3.0. Sex (p=0.0001),
recurrence (p=0.0001), symptomatic (p=0.013),
volume (p=0.014), edema (p=0.001), and calcification
(p=0.0001) were correlated with the MIB-1 staining index
by chi-square test; age, skull base, and multiple were
not.
Meningothelial, transitional, and fibrous meningiomas
were the three major subtypes, and they accounted for
about three fourth of the total. Two hundred and ninety-six
meningiomas belonged to grade I; 28 grade II; and 18 grade
III. MIB-1 staining index in 56 of 296 grade I meningiomas
was ≥ 3.0; that in 27 of 28 grade II; and that in 17 of 18
grade III, respectively (Table 2).
Logistic regression analysis demonstrated that male
(odds ratio [OR], 2.374, p=0.003), recurrence (OR, 7.574,
p=0.0001), skull base (OR, 0.540, p=0.035), calcification
(OR, 0.498, p=0.019) were independent risk factors for a
Table 1 Characteristics and MIB-1 staining index in 342 meningio-
mas
MIB-1 staining index (%)
Factor <3.0 ≥3.0 P Value
Age (years) 0.937
-49 65 24
50- 72 32
60- 79 34
70- 26 10
Sex (male/female) 46/196 43/57 0.0001
Recurrence (yes/no) 14/228 34/66 0.0001
Symptomatic (yes/no) 133/109 70/30 0.013
Skull base (yes/no) 119/123 38/62 0.059
Volume (cm
3) 0.014
-9.9 113 37
10- 53 15
20- 76 48
Multiple (yes/no) 15/227 9/91 0.244
Edema (yes/no) 82/160 54/46 0.001
Calcification (yes/no) 97/145 20/80 0.0001
Total 242 100
294 Neurosurg Rev (2006) 29:293–297high MIB-1 staining index (≥ 3.0); age, symptomatic,
volume, multiple, and edema were not (Table 3).
Discussion
We analyzed the relationship of the MIB-1 staining indices
to the characteristics of 342 consecutive patients with
meningioma surgically removed between 1995 and 2004
by logistic regression analysis. Logistic regression analysis
demonstrated that male (odds ratio [OR], 2.374, p=0.003),
recurrence (OR, 7.574, p=0.0001), skull base (OR, 0.540,
p=0.035), calcification (OR, 0.498, p=0.019) were indepen-
dent risk factors for a high MIB-1 staining index (≥ 3.0);
age, symptomatic, volume, multiple, and edema were not.
The relationship between the growth rate or MIB-1
staining index and age has been controversial: a higher
MIB-1 staining index and higher growth rate were observed
for younger patients [11, 13, 21]; but not in other reports [1,
12, 15, 19]. Our series of 342 patients with meningioma
showed no relation.
It is well known that atypical and anaplastic meningio-
mas are predominant in males [10]. Matsuno et al. [11]
reported that the mean MIB-1 staining index in 50 male
patients was 5.5%, whereas that in 77 female patients was
2.7%. Our findings show that male (odds ratio [OR], 2.374,
p=0.003) was an independent risk factor for a high MIB-1
staining index. We also found a higher MIB-1 staining
index in males even in grade I meningioma (MIB-1 staining
index in 32 of 226 females, and in 24 of 70 males was
≥ 3.0, p=0.0001, chi-squire test).
Recurrence (OR, 7.574, p=0.0001) was the most
significant independent risk factor for a high MIB-1
staining index (≥ 3.0). Therefore, we propose prompt
management for recurrent meningiomas. In most of the
recurrent meningiomas, the MIB-1 staining index was
higher at the time of recurrence than at the time of
initial surgery [1, 11, 19]. Changes in histological
morphology and malignant transformation are also known
in meningiomas.
Although there is a significant difference in the MIB-1
staining index between symptomatic and non-symptomatic
meningiomas by chi-square test, symptomatic is not an
independent risk factor for a high MIB-1 staining index.
Meningiomas commonly present with seizure disorders,
and are associated with location, perilesional edema, and
convexity location. Symptoms and signs of elevated
intracranial pressure could be due to the large size of
meningioma itself, or to the pronounced cerebral swelling
resulting from reactive vasogenic edema. Focal neurolog-
ical deficits caused by meningiomas are generally related to
direct local brain, cranial-nerve compression, and can be
predicted from the site of origin of the tumor [20]. Thus,
symptomatic meningioma may not be related to a high
MIB-1 staining index. The growth rate of incidental
meningioma may be similar to that of symptomatic
meningioma.
Our results demonstrated that skull base (OR, 0.540,
p=0.035) is an independent risk factor for a high MIB-1
staining index. No relationship has been reported between
the MIB-1 staining index and the location of meningiomas
[15, 19]. In general, the surgical risk for meningiomas is
higher in skull base. A low proliferative potential in skull
base meningiomas should be taken into consideration
especially when treating elderly patients with asymptomatic
meningiomas [9, 16].
Table 2 Histological subtypes and MIB-1 staining index of 342
meningiomas
Subtype MIB-1 staining index (%) Total
<3.0 ≥3.0
Grade I
Meningothelial 106 28 134
Fibrous 67 13 80
Transitional 43 13 56
Psammomatous 6 0 6
Angiomatous 13 2 15
Microcystic 1 0 1
Secretory 1 0 1
Lymphoplasmacyte-rich 1 0 1
Metaplastic 2 0 2
240 56 296
Grade II
Atypical 1 26 27
Chordoid 0 1 1
12 7 2 8
Grade III
Rhabdoid 0 1 1
Papillary 1 1 2
Anaplastic 0 15 15
11 7 1 8
Total 242 100 342
Table 3 Logistic regression analysis for factors independently related
to MIB-1 staining index
Factor Odds ratio 95%CI P Value
Age 1.109 0.841–1.461 0.464
Sex 2.374 1.336–4.219 0.003
Recurrence 7.574 3.558–16.124 0.0001
Symptomatic 1.468 0.774–2.784 0.240
Skull base 0.540 0.305–0.956 0.035
Volume 1.332 0.944–1.879 0.103
Multiple 1.027 0.398–2.651 0.957
Edema 1.508 0.838–2.711 0.170
Calcification 0.498 0.278–0.892 0.019
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staining index in tumor size by chi-square test [15], tumor
size is not an independent risk factor for a high MIB-1
staining index. The tumor volume is associated with the
annual growth rate but not with doubling time [13, 16, 21].
Assuming that a tumor shows a constant relative volume
increase, larger tumors will show higher growth rates if the
annual volume increase is expressed in absolute values.
Large tumors should be carefully observed even though the
initial volume is not a risk factor for a high MIB-1 index,
and it is not correlated with doubling time.
The etiology of peritumoral brain edema associated
with meningiomas is multifactorial. Factors that may
influence the etiology of peritumoral edema include tumor
size, histological subtypes, vascularity, venous stasis, and
brain invasion [1, 4]. Ide et al. [4] found a significant
correlation of both the MIB-1 staining index and tumor size
with the extent of edema. A high MIB-1 staining index
itself did not seem to be directly responsible for perifocal
edema, since our logistic regression analysis demonstrated
that edema is not an independent risk factor for a high MIB-
1 index [15].
Tumors with calcification grew significantly less than
those without calcification [9, 13, 16]. Absence of
calcification on CT correlated strongly with doubling time
[5]. Diffusely calcified meningiomas had a low mean MIB-
1 staining index of 0.57%. Focally calcified tumors showed
a relatively low proliferative potential (0.92%) compared
with that of noncalcified tumors (1.75%) [15]. The results
are always consistent when the relationship between
calcification and proliferative potential or growth rate is
compared. We also confirmed this characteristic in menin-
gioma (OR, 0.498, p=0.019).
In conclusion, male, recurrence, non-skull base, absence
of calcification are independent risk factors for a high
proliferative potential. These should be taken into consid-
eration when managing meningiomas.
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Comments
Jürgen R. E. Bohl, Mainz, Germany
The aim of this investigation on 342 patients with meningiomas
was to determine the clinical and radiological features related to their
proliferative capacity using the MIB-1 staining index. This seems to
296 Neurosurg Rev (2006) 29:293–297be justified as other authors had found, that in cases of meningiomas
with a MIB-1 index of 3 or more percent the tumor volume doubling
time was less than 2 years (see reference No. 12: Nakaguchi et al.).
Therefore it would be of great benefit for all therapeuticstrategies to
know some independent risk factors for a high growth rate of a
meningioma prior to surgical intervention and histopathological
investigation.
H. Kasuya et al. could demonstrate by using a logistic regression
model that in their carefully documented series of 342 meningiomas
there were four independent risk factors for a high proliferative
potential. These were male, tumor recurrence, non-skull base
localization and absence of calcification. Age, symptomatic behaviour,
tumor volume, multiplicity and peritumoral edema proved not to be
independent risk factors.
In general a lot of scientific work has been done in order to predict
the outcome of a disease, especially to determine the prognosis of
tumor patients. All people and institutions involved in the therapy or
cure of a tumor disease want to know: How long will the patient
survive?
Primarily the grading of brain tumors was based on clinical
observations of survival rates and mortality diagrams. The grading of
meningiomas according to the WHO-classification of brain tumors
takes into consideration not only the mitotic activity and the
proliferation indices but also some other histopathologic character-
istics, that had proved to be important concerning the course of the
disease. The survival rate was the essential criterion for evaluating the
importance of many different features.
Thus it happened, that in the series of H. Kasuya et al. there were
56 of 296 grade I meningiomas with a MIB-1 staining index of greater
than 3%, and that in the groups of grade II and even grade III
meningiomas there were two tumors (2 out of 46) with a low
proliferation index (less than 3 %). Under the assumption that the
grading of tumors reflects the clinical course of the disease, these
observations hint to the fact, that the proliferating potential of a tumor
is not the only and perhaps also not the most important property of a
tumor, in concern to the outcome of the disease.
These statistically established phenomena of a tumor disease are of
an inestimable value for therapeutic decisions; but we always should
bear in mind, that in a very single case, in a patient just sitting in front
of you, all these well known “facts” might be totally wrong and not
suitable at all. Because the patient and his tumor (the tumor and its
host) are performing always a very individual symbiotic process that is
unique in the world.
Kaoru Kurisu, Hiroshima, Japan
The authors analyzed the relationship of MIB-1 indices to
characteristics of 342 consecutive patients with meningioma surgically
removed between 1995 and 2004 in Tokyo Women’sM e d i c a l
University by logistic regression analysis. The MIB-1 staining index
in 100 of 342 meningiomas was equal to or bigger than 3.0;56 of 296
were grade I using the WHO classification, 27 of 28 grade II, 17 of 18
grade III. The authors concluded that male, recurrence, non-skull base
location and absence of calcification are independent risk factors for a
high proliferative potential of meningiomas from the results of MIB-1
staining of each operative specimen. This is a very clear and important
conclusion. As there are in Japan many CT scanners and MRI
machines and all people living in Japan have medical insurance with
relatively low cost, people can be easily checked by CT or MRI when
they present with minor symptoms such as slight headache or vertigo.
The chance is thus high to detect meningiomas almost incidentally.
Recently in Japan, it was found that meningioma is the most common
primary brain tumor (Report of Brain Tumor Registry of Japan, 1969–
1996, 11th Edition). According to the registry in 1996, the incidences
of meningiomas, all gliomas, pituitary adenomas and schwannomas
are 27.8%, 22.8%, 18.3% and 9.6%, respectively. This tendency of
incidences of each brain tumor has been lasting for several years. On
the other hand, I recognize that glioma is the most common primary
brain tumor in other countries in the world. Additionally, the life
expectancy of Japanese people is one of the longest in the world. The
rate of people older than 65 years out of the total population of Japan
will be one fourth in 2015 by statistical inference. It is, therefore,
important to know the natural course of each brain tumor to make
enough and beneficial informed consent to the patients with brain
tumors. I believe this paper provides us the proper information for
patients with meningioma. Presently, we usually check patients with
an incidentally found meningioma by control image after 3 months to
exclude the progressive subtypes like atypical or anaplastic
meningioma.
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